First treatment approved for multicentric Castleman’s disease in Europe

Janssen’s SYLVANT (siltuximab) has been approved by the European Commission (EC) for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative.

Source: Pharmacy Europe - June 6, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: Haematology janssen Latest News MCD multicentric Castleman’s disease siltuximab SYLVANT Source Type: news